2 news items
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
OVID
TAK
17 Jun 24
opportunities in the near term. Our R&D and financial strategy is independent of soticlestat’s outcome. We will advance our pipeline
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK
17 Jun 24
was adjudicated independently by the Epilepsy Study Consortium. The study treatment period was 16 weeks including a 4-week titration period and 12 weeks
- Prev
- 1
- Next